XELOX plus bevacizumab as a ifrst-ine treatment for Chinese patients with metastatic colorectal cancer:a retrospective study
- VernacularTitle:XELOX方案联合贝伐单抗作为一线药物治疗转移性结肠癌的回顾性研究
- Author:
Jidong CAI
;
Weijun LI
;
Linhua LI
- Publication Type:Journal Article
- Keywords:
XELOX regimen;
bevacizumab;
metastatic colorectal cancer;
retrospective study
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(2):68-70,73
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efifcacy and safety of XELOX plus bevacizumab as a ifrst-ine treatment for Chinese patients with metastatic colorectal cancer. Methods In this study, we retrospectively reviewed cases in which XELOX plus bevacizumab were administered in order to evaluate its efifcacy and safety in clinical practice.In total, 40 patients with mCRC who presented at Fuchu Hospital received XELOX plus bevacizumab as a ifrst?line treatment from September, 2009 to April, 2012. Eligible patients had histologically conifrmed mCRC. XELOX consisted of a 2-h intravenous infusion of oxaliplatin 130 mg/m 2 on day 1 plus oral capecitabine 1,000 mg/m 2 twice daily for two weeks of athree?week cycle. Overall survival (OS) and survival benefit were analyzed when patients continued with XELOX plus bevacizumab beyond disease progression. Results The median progression?free survival (PFS) was 290 days [95%conif-dence interval (CI):222?409 days] and the median OS was 816 days (95%CI:490?842 days). The response rate (RR:complete plus partial response) was 67.5%, and the disease control rate (RR plus stable disease) was 90%. Conclusion XELOX plus bevacizumab may be considered a routine ifrst?line treatment option for patients with mCRC.
